Wet Macular Degeneration Market Report and Forecast 2025-2034

Wet Macular Degeneration Market Overview

Wet macular degeneration (or neovascular AMD) is a long-term disease that affects central vision in senior citizens. Wet macular degeneration is a more serious condition and is a type of AMD marked by a severe, rapid loss of central vision in the retina where macular degeneration has occurred. This condition develops when the small blood vessels beneath the macula of the retina swarm and ooze out fluids like blood. While the rest of the retina is involved in the peripheral vision, the macula is responsible for the central vision, necessary for reading or identifying faces. Symptoms are effectively controlled by early intervention, and medications like anti-VEGF injections can delay the progression of the condition.

Wet Macular Degeneration Market Growth Drivers

Increasing Aging Population to Boost the Market Growth

In a report, the World Health Organization (WHO) highlighted that with increasing life expectancy, a large number of individuals will reach 60 or older by 2050. Wet macular degeneration cases are bound to surge with the increasing incidence of the geriatric population base, leading to increased demand for treatment among the elderly with vision-related diseases.

FDA Approval Boosts the Market Growth

In September 2024, Pavblu, the fifth biosimilar referencing Eylea (aflibercept), was approved by the FDA for the treatment of retinal conditions such as wet age-related macular degeneration. Pavblu, developed by Amgen, was approved after a phase 3 study with 576 patients from various countries. It is one of several biosimilars that got approval in 2024, along with Yesafili, Opuviz, Ahzantive, and Enzeevu. There is a growing emphasis on early detection and preventive healthcare. Increasing approvals from essential regulatory authorities is expected to boost the market value in the forecast period.

Wet Macular Degeneration Market Trends

Wet Macular Degeneration Market Segmentation

Wet Macular Degeneration Market Share

Market Segmentation Based on the Route of Administration Set to Witness Substantial Growth

The market is segmented into intravenous route and intravitreal route based on the route of administration. Among these, the intravitreal method is expected to dominate the market because it directly administers drugs into the eye, resulting in improved treatment results and fewer overall side effects. Medications such as Ranibizumab (Lucentis) and Aflibercept (Eylea) are often given through injections directly into the eye. This technique enables focused treatment of the retina, effectively preventing the growth of abnormal blood vessels. Due to its established efficacy and lower risks when compared to systemic delivery, intravitreal therapy continues to be considered the preferred treatment method for wet AMD.

Segmentation Based on End User Holds a Significant Market Share

The market is divided into hospitals, clinics, ambulatory surgical centers, homecare settings, and others. Among these, hospitals and clinics are expected to dominate the market because of their specialized ophthalmologists and advanced diagnostic equipment. They provide thorough treatment, which includes giving anti-VEGF medications such as Lucentis and Eylea via injections into the eye. Ambulatory surgical centers also hold a substantial share due to their affordability, while homecare settings are utilized for remote monitoring and occasional medical care.

Wet Macular Degeneration Market Analysis by Region

Based on region, the market report covers the United States, EU-4, and the United Kingdom (Germany, France, Italy, Spain, United Kingdom), Japan, and India. Due to advanced healthcare systems and substantial investment in research, the United States is expected to dominate the market. Factors like increasing elderly populations and lifestyle-related risks impact the market in this area. The government's backing promotes market expansion through leadership in clinical trials and innovative treatments such as targeted therapies and immunotherapies. The market is growing due to greater emphasis on early detection and personalized treatment choices.

Leading Players in the Wet Macular Degeneration Market

Other companies include Panoptica Pharma, Bausch + Lomb, Regeneron Pharmaceuticals Inc., Ocugen Inc., REGENXBIO Inc., and Oxurion NV, among others.

Key Questions Answered in the Wet Macular Degeneration Market

• What was the wet macular degeneration market value in 2024?
• What is the wet macular degeneration market forecast outlook for 2025-2034?
• What are the regional markets covered in the EMR report?
• What is the market breakup based on the disease stage?
• What is the market segmentation based on the treatment type?
• What is the market breakup based on the route of administration?
• What major factors aid the wet macular degeneration market demand?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major wet macular degeneration market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players in the wet macular degeneration market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
• How does the management of intermediate AMD differ from late-stage AMD?
• What role do anti-VEGF drugs play in wet AMD treatment?
• Why is the intravitreal route the preferred method for wet AMD treatment?
• Why does the United States lead the wet AMD market?
• What factors drive the wet AMD market in EU-4 and the UK?